Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
Effect of Isomaltooligosaccharides on Intestinal Bacterial Translocation in Patients With Liver Cirrhosis: a Single-center, Single-arm Study
Nanfang Hospital, Southern Medical University
18 participants
Nov 25, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.
Eligibility
Inclusion Criteria4
- Age from 18-75.
- Cirrhotic patients.
- Decompensation event: ascites.
- LPS>0.45EU/ml.
Exclusion Criteria14
- Pregnant or breast-feeding.
- Active bacterial or fungal infection.
- Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
- Diagnosis of EASL-ACLF.
- Diarrhea.
- Malignancy.
- Anticipated short survival time.
- Adverse reactions or allergies to oral carbohydrate preparations.
- Substance abuse or addiction.
- Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
- Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
- Be unsuitable for participating in this trial.
- Participated in any drug trial within the past month
- History of antibacterial or fungal use within 1 week prior to screening
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will still receive standard treatment, including medicine and other invasive treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06134544